Navigation Links
Application of Hepatocyte Growth Factor - New Hope for Many Conditions
Date:12/2/2013

BEIJING, Dec. 2, 2013 /PRNewswire/ -- ReLife International Medical Center researches hepatocyte growth factors. HGF is a paracrine cellular growth, motility and morphogenic factor secreted by mesenchymal cells. By acting as a multi-functional cytokine, HGF is being applied in treatments for not only hepatic conditions but also many other diseases in nowadays due to its angionenic, anti-fibrotic and antiapoptosis actions. [1, 2]

Ischemic diseases  HFG can stimulate the migration, proliferation and neovascularization of vascular endothelial cells. In addition, HGF is capable of protecting the nerves cell by increasing neuronal survival and axonal regeneration. HGF has proven to be effective in gene therapy for limb ischemia conditions and myocardial ischemia. Decreasing of ulceration area and pain relief have been shown in patients with lower limb ischemia conditions after being treated with HGF. Combination of mesenchymal stem cells - MSCs with adenovirus carrying HGF can promote neovascularization in chronic ischemic myocardium, inhibit apoptosis and improve the cardiac functions.

Diabetes  HFG can inhibit the apoptosis of endothelial cells under hyperglycemic environment and promote the repair process of vascular endothelial cells, which is an ideal treatment for diabetic vascular complications. On the other hand, HGF can inhibit the fibrosis of renal interstitium of Diabetic Nephropathy. It can also promote MSCs to differentiate into islet cells in stem cell therapy.

Others  HFG is able to relieve neuron hypoxia injuries and promote neural stem cells to differentiate into neuronal cells. HGF can also protect human pulmonary microvascular endothelial cells and promote the repair of damage resulting from a pulmonary injury, etc.

With its multi-functional characteristics, HGF might have a bright future in the medical field.

[1] Azuma J, Taniyama Y, Takeya Y, et al. Angiogenic and antifibrotic actions of hepatocyte growth factor improve cardiac dysfunction in porcine ischemic cardiomyopathy. Gene Ther, 2006, 13: 1206--1213

[2] Jayasankar V, Woo Y J, Pirolli T J, et al. Induction of angiogenesis and inhibition of apoptosis by hepatocyte growth factor effectively treats postischemic heart failure. J Card Surg, 2005, 20: 93--101


'/>"/>
SOURCE ReLife International Medical Center
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Applications due in December for Photonics Innovation Village
2. Mesenchymal Stem Cells - Advances & Applications 2013
3. Convey Computer to OEM Dell Servers to Accelerate Data Intensive Applications for Data Centers
4. Convey Computer Announces New Hybrid-Core Coprocessor to Accelerate Data-Intensive Applications
5. Biomarkers: Discovery Techniques and Applications - A Global Market Overview
6. Applications Due This Month for SPIE Startup Challenge at Photonics West 2014
7. MultiCell Technologies Files U.S. Patent Application for Targeted Delivery of MCT-485, a Noncoding miRNA for Cancer Treatment
8. Advances for Food Safety, Energy, Security and More on the Program for SPIE Micro+Nano Materials, Devices, and Applications
9. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
10. CIRTEMO to Launch Multivariate Optical Element Platform for Neuroscience Applications
11. Tunisia Hosts First African Summer School on Optics and Applications to Sustainable Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
Breaking Biology Technology:
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):